International Journal of Drug Delivery Technology
Volume 15, Issue 3

Extraction and Isolation of Bioactive Compounds from Blatta orientalis 

Sanjay Kumar*, Nidhi Bais 

Oriental College of Pharmacy & Research, Oriental University, Indore, MP-453555, India 

Received: 27th Apr, 2025; Revised: 6th Jul, 2025; Accepted: 29th Jul, 2025; Available Online: 25th Sep, 2025 

ABSTRACT

The study investigates the extraction, isolation, and characterization of bioactive compounds from Blatta orientalis, an insect traditionally recognized in ethnomedicine for its medicinal properties. With an increasing demand for novel pharmacologically active compounds, insects represent an untapped resource in the search for new therapeutics. This research aimed to extract bioactive compounds from B. orientalis using ethanol as a solvent, followed by a series of purification techniques to isolate the key active components. The bioactive compounds were isolated through thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC), ensuring compound purity for further analysis. Structural characterization was performed using advanced spectroscopic methods, including Fourier-transform infrared spectroscopy (FTIR), nuclear magnetic resonance (NMR), and mass spectrometry (MS), to elucidate the functional groups, molecular structure, and molecular weight of the isolated compounds. The findings revealed multiple bioactive compounds, including alkaloids and phenolic compounds, with potential antimicrobial and anti-inflammatory properties. This study contributes to the understanding of B. orientalis as a source of bioactive compounds, highlighting its potential applications in developing natural therapeutics. The comprehensive approach combining chromatographic and spectroscopic techniques allowed for the effective identification of compounds, setting a foundation for further pharmacological studies. The insights gained underscore the relevance of B. orientalis as a valuable source of bioactive compounds and emphasize the need for further research to fully explore its therapeutic potential. This study thus paves the way for the potential development of B. orientalis-derived products in natural medicine and pharmacology.

Keywords: Blatta orientalis, Bioactive compounds, Extraction, Isolation, Chromatographic, Spectroscopic characterization

How to cite this article: Sanjay Kumar, Nidhi Bais. Extraction and Isolation of Bioactive Compounds from Blatta orientalis. International Journal of Drug Delivery Technology. 2025;15(3):1245-57. doi: 10.25258/ijddt.15.3.45

REFERENCES

  1. Patil MR, Bihari A. A comprehensive study of p53 protein. Journal of Cellular Biochemistry. 2022 Dec;123(12):1891-937. https://doi.org/10.1002/jcb.30331
  2. Chinnam M, Xu C, Lama R, Zhang X, Cedeno CD, Wang Y, Stablewski AB, Goodrich DW, Wang X. MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity. PLOS Genetics. 2022 May 19;18(5):e1010171. https://doi.org/10.1371/journal.pgen.1010171
  3. Cutty SJ, Hughes FA, Ortega-Prieto P, Desai S, Thomas P, Fets LV, Secrier M, Barr AR. Pro-survival roles for p21 (Cip1/Waf1) in non-small cell lung cancer. British Journal of Cancer. 2024 Dec 20:1-7. https://doi.org/10.1038/s41416-024-02928-9
  4. Wang J, Thomas HR, Li Z, Yeo NC, Scott HE, Dang N, Hossain MI, Andrabi SA, Parant JM. Puma, noxa, p53, and p63 differentially mediate stress pathway induced apoptosis. Cell Death & Disease. 2021 Jun 30;12(7):659. https://doi.org/10.1038/s41419-021-03902-6
  5. Palomer X, Salvador JM, Griñán-Ferré C, Barroso E, Pallàs M, Vázquez-Carrera M. GADD45A: With or without you. Medicinal Research Reviews. 2024 Jul;44(4):1375-403. https://doi.org/10.1002/med.22015
  6. Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, Lei H, Wang J, Xie X, Cheng B, Li Q, Zhang H, Di C. Mutant p53 in cancer: From molecular mechanism to therapeutic modulation. Cell Death & Disease. 2022 Nov 18;13(11):974. https://doi.org/10.1038/s41419-022-05408-1
  7. Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Sasaki K, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leukemia & Lymphoma. 2024 Aug 23;65(10):1511-5. https://doi.org/10.1080/10428194.2024.2363440
  8. Chasov V, Davletshin D, Gilyazova E, Mirgayazova R, Kudriaeva A, Khadiullina R, Yuan Y, Bulatov E. Anticancer therapeutic strategies for targeting mutant p53-Y220C. Journal of Biomedical Research. 2024 May;38(3):222-32. https://doi.org/10.7555/JBR.37.20230093
  9. Stephenson Clarke JR, Douglas LR, Duriez PJ, Balourdas DI, Joerger AC, Khadiullina R, Bulatov E, Baud MG. Discovery of nanomolar-affinity pharmacological chaperones stabilizing the oncogenic p53 mutant Y220C. ACS Pharmacology & Translational Science. 2022 Oct 11;5(11):1169-80. https://doi.org/10.1021/acsptsci.2c00164
  10. Hua Y, Dai X, Xu Y, Xing G, Liu H, Lu T, Chen Y, Zhang Y. Drug repositioning: Progress and challenges in drug discovery for various diseases. European Journal of Medicinal Chemistry. 2022 Apr 15;234:114239. https://doi.org/10.1016/j.ejmech.2022.114239
  11. Sohraby F, Aryapour H. Rational drug repurposing for cancer by inclusion of the unbiased molecular dynamics simulation in the structure-based virtual screening approach: Challenges and breakthroughs. Seminars in Cancer Biology. Academic Press. 2021 Jan 1;68:249-57. https://doi.org/10.1016/j.semcancer.2020.04.007
  12. Han IS, Thayer KM. Reconnaissance of allostery via the restoration of native p53 DNA-binding domain dynamics in Y220C mutant p53 tumor suppressor protein. ACS Omega. 2024 Apr 22;9(18):19837-47. https://doi.org/10.1021/acsomega.3c08509
  13. Bethi S, Shirole R, More V, Thorat M, Mohapatra S, Tare H. Uncovering the anticonvulsant mechanisms of Saussurea Lappa: A network pharmacology and molecular docking approach. Palestinian medical and pharmaceutical journal. 2025 Jan 1;9999(9999):None- (Pal. Med. Pharmaceutical Journal)
  14. de Vries I, Perrakis A, Joosten RP. PDB‐REDO in computational-aided drug design (CADD), Open Access Databases and Datasets for Drug Discovery. (edited by: A Daina, M Przewosny & V Zoete). John Wiley & Sons: Chichester. 2024 Feb 5:201-29. https://doi.org/10.1002/9783527830497.ch7
  15. Gholipour Z, Fooladi AA, Parivar K. Targeted therapy with a novel superantigen-based fusion protein against interleukin-13 receptor α2-overexpressing tumor cells: An in-silico study. Iranian Journal of Pathology. 2024 Feb 15;19(2):193-204. https://doi.org/10.56042/ijnpr.v15i4.9059
  16. Bethi S, Shirole R, Ghangale G. Computational exploration of multitarget effects of curcumin in breast cancer treatment. Pharmaceutical Fronts. 2025 (efirst);7(1):e41-52. https://doi.org/10.1055/a-2522-0009
  17. Malla R, Viswanathan S, Makena S, Kapoor S, Verma D, Raju AA, Dunna M, Muniraj N. Revitalizing cancer treatment: Exploring the role of drug repurposing. Cancers. 2024 Apr 11;16(8):1463. https://doi.org/10.3390/cancers16081463
  18. Deore S, Tajane P, Bhosale A, Thube U, Wagh V, Wakale V, Tare H. 2-(3, 4-dihydroxyphenyl)-5, 7-Dihydroxy-4H-Chromen-4-One flavones based virtual screening for potential JAK inhibitors in inflammatory disorders. International Research Journal of Multidisciplinary Scope. 2024;5(1):557-67. https://doi.org/10.47857/irjms.2024.v05i01.0268
  19. Tajane P, Kayande N, Bhosale A, Deore S, Tare H. Design and discovery of silmitasertib-based drugs as a potential casein kinase II inhibitor for cholangiocarcinoma through hybrid in-silico ligand-based virtual screening with molecular docking method. International Journal of Drug Delivery Technology. 2023;13(4):1514-9. https://doi.org/10.25258/ijddt.13.4.60
  20. Liu Y, Yang X, Gan J, Chen S, Xiao ZX. Cao Y. CB-Dock2: Improved protein–ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Research. 2022 Jul 5;50(W1):W159-64. https://doi.org/10.1093/nar/gkac394
  21. Suvarchala Reddy NV, Ganga Raju M, Anusha V, Gaikwad A, Pulate C, Mahajan K, Tare H. Investigation of potential antiurolithiatic activity and in silico docking studies of Karpura shilajit. International Journal of Health Sciences. 2022;6(supplement 4):8900-16. https://doi.org/10.53730/ijhs.v6nS4.11875